Bremelanotide (PT-141) Development from Melanotan II
The sexual side effects observed with Melanotan II led to the development of Bremelanotide (PT-141) as a dedicated sex drive drug. This involved a molecular tweak to the original peptide structure. Notably, darker skin pigmentation remains listed as a side effect for Bremelanotide due to its mechanism involving melanocortin receptors.
Melanotan II Discovery via Erection Side Effect
In 1996, scientists were testing Melanotan II as a tanning peptide. They observed that users experienced significant erections lasting hours. This side effect was linked to the drug's interaction with a brain receptor involved in nitric oxide release, which is also wired into sexual function.
Melanocortin Receptor Class Effect: Nausea as a Shared Side Effect Across Multiple Peptides
Nausea is identified as a class-wide side effect of melanocortin receptor agonist peptides, not unique to PT-141 alone. PT-141, Melanotan II, and setmelanotide all share this side effect profile due to their shared mechanism of MC4R activation adjacent to the brain's vomiting center. Understanding this class effect has implications for anticipating and managing side effects across all melanocortin-targeting peptides.
Melanotan II Shares Nausea Side Effect Profile with PT-141
PT-141 is derived from Melanotan II, and both peptides share the nausea side effect due to their shared melanocortin receptor class activity. This indicates the nausea is a class effect of melanocortin agonists rather than unique to PT-141 specifically. No dosage information is provided for either peptide.